Ultragenyx stock remains a buy at TD Cowen despite interim analysis miss

Ultragenyx Pharma (NASDAQ:RARE) shares are trading near 52-week lows after its Phase 3 setrusumab trial for osteogenesis imperfecta failed to meet interim analysis thresholds. Despite this setback, multiple investment firms including TD Cowen, Morgan Stanley, and Wells Fargo have maintained positive ratings and significant price targets, citing the drug's confirmed safety profile allowing trial continuation to final analysis in December 2025, strong liquidity, and high conviction in ultimate efficacy. Analysts view the current stock weakness as a buying opportunity, anticipating substantial upside if final results validate the therapy.

Analysis

Ultragenyx Pharma (RARE) is facing a significant valuation disconnect following a clinical trial setback. The company's stock is trading near its 52-week low after its Phase 3 Orbit study for setrusumab failed to meet its interim analysis endpoint. Despite this negative catalyst, a strong consensus of investment firms, including TD Cowen, Morgan Stanley, and Canaccord Genuity, have maintained Buy or Overweight ratings with price targets ranging from $65 to $136, implying substantial upside from the current sub-$30 level. This bullish outlook is predicated on several key factors: the drug's acceptable safety profile confirmed by the Data Monitoring Committee, which allows the trial to continue to its final analysis; a high conviction from analysts like TD Cowen, which estimates a greater than 70% probability of success in the final readout expected by December 2025; and the company's robust financial position, evidenced by a current ratio of 2.4, suggesting ample liquidity to fund operations through the trial's conclusion. The market has priced in the immediate trial disappointment, while analysts are focusing on the long-term potential, viewing the present weakness as a compelling entry point ahead of the definitive data.

Key Decisions for Investors

• Investors with a high-risk tolerance and a long-term horizon could consider the current stock price a strategic entry point, capitalizing on the dislocation between the market's reaction and bullish analyst price targets.
• The primary catalyst is the final trial data expected by the end of 2025, making any investment in RARE a long-duration, binary-event-driven play that requires patience.
• Given the company's strong liquidity ratio of 2.4, immediate financing risk appears low, but investors should continue to monitor cash burn rates to ensure the firm remains well-funded through the final data readout.
• Acknowledge that a long position is contrarian to the recent market price action; a negative outcome in the final trial analysis would likely lead to significant further downside, representing the primary risk to this investment thesis.